Sirolimus

Sirolimus, also known as Rapamune, is an immunosuppressive medication belonging to the class of drugs called mTOR inhibitors. It is used to prevent the body’s immune system from attacking transplanted organs, helping to ensure the success of the transplant. Sirolimus works by inhibiting the growth and proliferation of T-cells, a type of white blood cell involved in the immune response.
Sirolimus is often used in combination with other immunosuppressive medications, such as corticosteroids and mycophenolate mofetil, to provide a comprehensive approach to managing post-transplant immune reactions. This combination therapy helps to reduce the risk of organ rejection while minimizing the side effects associated with individual medications.
The use of sirolimus in transplant patients has been shown to reduce the risk of acute rejection episodes, particularly in kidney transplant recipients. Additionally, sirolimus has been found to have a favorable impact on long-term graft function and patient survival.
Sirolimus is available in tablet form and is typically administered once daily. The dosage and duration of treatment will depend on the patient’s specific medical condition, the type of transplant, and the patient’s response to therapy.
As with any medication, sirolimus can cause side effects. Common side effects include anemia, hyperlipidemia, and increased blood pressure. Patients should be closely monitored for these side effects and receive appropriate medical care if they occur.